Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a new dressing make skin graft donor sites less painful?

NCT ID NCT07734519

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Aug 26, 2026 · Updated 4 times

Summary

This trial tests whether a new dressing called Pelashield reduces pain and improves scar appearance compared to the standard Xeroform dressing at skin graft donor sites. Each participant will have their donor site split in half, with one half receiving Pelashield and the other Xeroform, allowing direct comparison. The study enrolls adults undergoing split-thickness skin grafts and measures pain scores and scar quality over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pelashield dressing (a new skin graft donor-site dressing) compared to Xeroform dressing
What this could lead to
If Pelashield reduces pain or improves scar appearance, it could become a better option for people undergoing skin grafts.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The new dressing might not be better than the standard one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergoing split-thickness skin graft harvest, with a donor site sufficiently large to allow division into two comparable halves for randomized dressing application. * Donor site located in an area amenable to standardized photography and serial appearance assessment. * Ability to provide informed consent. * Willingness and ability to participate in scheduled follow-up visits for donor-site assessment, including standardized photography. * Donor-site management expected to follow the standardized study dressing protocol for the duration of the early healing period. Exclusion Criteria: * Inability, or anticipated inability, to reliably report pain within 1hour (or in recovery room) after surgery * Known allergy or hypersensitivity to lidocaine, silver-containing dressings, or other components of the study dressings. * Donor sites that are too small, irregularly shaped, or anatomically unsuitable to allow division into two comparable treatment halves. * Pre-existing skin disease at or adjacent to the donor-site region that may affect wound healing or scar appearance * Clinical situations in which the treating surgeon anticipates that protocol-based donor-site care cannot be maintained, including cases requiring non-standard dressings or adjunctive local therapies. * Anticipated inability to complete follow-up assessments, including inability to obtain evaluable standardized photographs at key time points. * Severe uncontrolled systemic conditions likely to significantly impair wound healing, at the discretion of the investigator (e.g., severe immunosuppression or other conditions making reliable donor-site healing unlikely). * Allergy to any local anesthetic * Allergy or sensitivity to silver * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Skin graft are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.